Loading
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Latest filing published 05 Dec 2022 for NORTHWEST BIOTHERAPEUTICS INC, €576k.
Insider track record
Disclosed buys
3
Disclosed sells
0
Signal history
No signal scores available.
Closed purchases
Market purchases
3
Positive at T+90
100%
Median T+90
+38.4%
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -83.8%Entry US$8.25 · Close at T+365 US$1.34
- +3.5%Entry US$19.96 · Close at T+365 US$20.65
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Jerry J. Jasinowski: trading record in brief
Jerry J. Jasinowski has filed trades across 5 companies (mainly through SEC (Form 4)), most often in Timken Co, Northwest Biotherapeutics Inc and Webmethods Inc. Between 3 October 2005 and 1 December 2022, the trades on record add up to 16 filings.
Every open-market trade on record is a purchase: 3 purchases worth €342k, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 10 share grants and 2 option exercises.
In size, the median ticket on the buying side is €153k. After 3 purchases with a full 90-day history, the hit rate stands at 100% and the median 90-day move at +38.4%. This is a record of the past, not a forecast.
On 5 December 2022 came the latest disclosure, a share grant for €576k in Northwest Biotherapeutics Inc. The last insider purchase was made public on 30 April 2015, 4,195 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Jerry J. Jasinowski
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations16 total
28,235 shares@ US$21.25100.0% of flowSeries C Convertible Preferred StockSEC:0001104659-22-124667:0
526,316 shares@ US$0.1913.5% of flowCommon StockSEC:0001104659-20-011526:0
35,715 shares@ US$5.60Common Stock, par value $0.001SEC:0001144204-15-026505:0
Canonical exit: 16 Jan 2013 (T+90)
43,602 shares@ US$4.80Common Stock, par value $0.001SEC:0001144204-15-026505:1
Canonical exit: 8 Jan 2013 (T+90)
4,000 sharesCommon StockSEC:0000098362-10-000062:0
2,500 sharesCommon StockSEC:0000098362-09-000086:0
34,992.4 shares0CommonSEC:0001225208-09-002848:0
4,000 shares@ US$16.41Common Stock, $1.25 par valueSEC:0000045876-08-000132:0
2,500 sharesCommon StockSEC:0000098362-08-000054:0
600 shares@ US$9.15Common StockSEC:0001209191-07-034276:0
2,500 sharesCommon StockSEC:0000098362-07-000075:0
1,321.83 shares@ US$7.70Common Stock (Phantom Shares)SEC:0001209191-06-053678:0
10,745.89 shares0Common Stock (Deferred Shares)SEC:0001209191-06-048344:0
53 shares@ US$11.82Common StockSEC:0001129633-06-000067:0
2,500 sharesCommon StockSEC:0001204048-06-000004:0
1,000 shares@ US$30.75Common StockSEC:0001204048-06-000002:0
Canonical exit: 7 May 2006 (T+90)
16 of 16 declarations
